[go: up one dir, main page]

MXPA03002875A - Composicion de vacuna y metodo de estabilizacion. - Google Patents

Composicion de vacuna y metodo de estabilizacion.

Info

Publication number
MXPA03002875A
MXPA03002875A MXPA03002875A MXPA03002875A MXPA03002875A MX PA03002875 A MXPA03002875 A MX PA03002875A MX PA03002875 A MXPA03002875 A MX PA03002875A MX PA03002875 A MXPA03002875 A MX PA03002875A MX PA03002875 A MXPA03002875 A MX PA03002875A
Authority
MX
Mexico
Prior art keywords
vaccine composition
stabilization method
stabilization
vaccine
composition
Prior art date
Application number
MXPA03002875A
Other languages
English (en)
Inventor
Alain Francon
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of MXPA03002875A publication Critical patent/MXPA03002875A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MXPA03002875A 2000-10-06 2001-10-08 Composicion de vacuna y metodo de estabilizacion. MXPA03002875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012805A FR2814957B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale et procede de stabilisation
PCT/FR2001/003097 WO2002028362A2 (fr) 2000-10-06 2001-10-08 Composition vaccinale et procede de stabilisation

Publications (1)

Publication Number Publication Date
MXPA03002875A true MXPA03002875A (es) 2003-07-14

Family

ID=8855080

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002875A MXPA03002875A (es) 2000-10-06 2001-10-08 Composicion de vacuna y metodo de estabilizacion.

Country Status (12)

Country Link
US (1) US6982088B2 (es)
EP (1) EP1357895A2 (es)
JP (1) JP2004526667A (es)
KR (1) KR100832551B1 (es)
CN (1) CN1298387C (es)
AU (2) AU2001295672B2 (es)
BR (1) BR0114350A (es)
CA (1) CA2424863A1 (es)
FR (1) FR2814957B1 (es)
MX (1) MXPA03002875A (es)
NZ (1) NZ525117A (es)
WO (1) WO2002028362A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618850A2 (pt) * 2005-11-21 2011-09-13 Sanofi Pasteur Ltd formulações de estabilização para vìrus recombinantes
WO2012028315A1 (en) * 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2839622A1 (en) 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
EP3569243A1 (en) 2011-06-28 2019-11-20 Inhibrx, LP Serpin fusion polypeptides and methods of use thereof
BR112014020930A2 (pt) * 2012-03-05 2017-06-27 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
JP6426695B2 (ja) 2013-03-14 2018-11-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 弱毒生アルファウイルス製剤のための組成物および方法
NL2018155B1 (en) * 2017-01-11 2018-07-25 Intervet Int Bv Oral vaccine against ruminant respiratory disease
US20240091102A1 (en) * 2019-10-16 2024-03-21 Janssen Vaccines & Prevention B.V. Vaccine Product
CN115697397A (zh) * 2020-04-11 2023-02-03 谢七一 接种脊髓灰质炎疫苗对抗冠状病毒
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617350C3 (de) * 1967-06-22 1979-09-06 Behringwerke Ag, 3550 Marburg Verfahren zur Inaktivierung von biologischem Material
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US3915764A (en) * 1973-05-18 1975-10-28 Westinghouse Electric Corp Sputtering method for growth of thin uniform layers of epitaxial semiconductive materials doped with impurities
DE3768232D1 (de) * 1986-12-19 1991-04-04 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
ATE218884T1 (de) * 1993-01-08 2002-06-15 Csl Ltd Impfstoffpräparate
EP0728195A1 (en) * 1993-10-12 1996-08-28 Chiron Corporation Methods for preserving recombinant viruses
US6379677B1 (en) * 2000-02-25 2002-04-30 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Streptococcus iniae vaccine

Also Published As

Publication number Publication date
CN1298387C (zh) 2007-02-07
EP1357895A2 (fr) 2003-11-05
FR2814957A1 (fr) 2002-04-12
WO2002028362A3 (fr) 2003-09-12
AU2001295672B2 (en) 2005-08-18
BR0114350A (pt) 2004-02-17
CA2424863A1 (en) 2002-04-11
AU9567201A (en) 2002-04-15
KR100832551B1 (ko) 2008-05-26
US20030190331A1 (en) 2003-10-09
CN1468091A (zh) 2004-01-14
JP2004526667A (ja) 2004-09-02
US6982088B2 (en) 2006-01-03
WO2002028362A2 (fr) 2002-04-11
KR20030096223A (ko) 2003-12-24
FR2814957B1 (fr) 2002-12-20
NZ525117A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20026175L (no) Vaksinesammensetning
PL363005A1 (pl) Szczepionki
NO20031483D0 (no) Vaksine
ATE322251T1 (de) Neurotoxin implantat
NO20024172L (no) Vaksine
DK1390066T3 (da) Vaccinesammensætning
ATE490327T1 (de) Impfstoffzusammensetzung
DE60139185D1 (de) Vernetzbare perfluoroelastomarzusammensetzung
HUP0302117A3 (en) Vaccine composition
NO20024890D0 (no) Implantat
FR2815535B1 (fr) Implant pediculaire
EP1284104A4 (en) PASTEURIZER
DK1265482T3 (da) Vandige formulationer og fremgangsmåde til fremstilling af samme
DE60125415D1 (de) Formeinsatz
NO20032122L (no) Forbedret behandling
NO20030239D0 (no) Modifisert virus
MXPA03002875A (es) Composicion de vacuna y metodo de estabilizacion.
CU23064A3 (es) Conjunto implante dental-transportador
DE10193450D2 (de) Gehörschutzstöpsel
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
FR2817889B1 (fr) Coffrage
SE0003877D0 (sv) New composition, method and use
ES1046518Y (es) Disposicion de bandera y similares.
IT1319677B1 (it) Composizione funghicida.
DOP2001000201A (es) Metodo y composición

Legal Events

Date Code Title Description
FG Grant or registration